ARWR

Arrowhead Pharmaceuticals, Inc.

61.50 USD

Last updated Oct 7, 04:18 UTC

Yesterday HIGH

$64.76

Yesterday LOW

$62.22

52w HIGH

$95.49

52w LOW

$34.61

EPS

-1.36

PE

-45.22

Next Earnings

Nov 24, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Arrowhead Pharmaceuticals, Inc. stock is down -27.74% since 30 days ago. The next earnings date is Nov 24, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40.74% of the previous 26 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

01 Oct 19:01	19 Jan, 2029	32.50	CALL	30	0
01 Oct 19:01	19 Jan, 2029	32.50	CALL	10	0
01 Oct 19:04	19 Jan, 2029	32.50	CALL	19	0
01 Oct 19:05	19 Jan, 2029	32.50	CALL	7	0
05 Oct 14:39	16 Oct, 2026	60.00	CALL	222	703
06 Oct 14:49	18 Dec, 2026	70.00	PUT	25	517
06 Oct 15:58	15 Dec, 2028	60.00	PUT	20	0
06 Oct 16:58	16 Oct, 2026	65.00	CALL	203	587
06 Oct 16:58	20 Nov, 2026	65.00	CALL	105	601
06 Oct 16:58	20 Nov, 2026	65.00	CALL	88	601

Advanced Data Unlock

Benzinga Newsdesk

Mon Jul 27, 2026

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $100 to $115.
Benzinga Newsdesk

Thu Jul 23, 2026

Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.
Benzinga Newsdesk

Thu Jul 23, 2026

Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126

Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $110 to $126.
Benzinga Newsdesk

Wed Jul 22, 2026

Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $90 to $115.
Vandana Singh

Wed Jul 22, 2026

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.
Benzinga Insights

Wed Jul 22, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million. Lakewood-Amedex (NASDAQ:LABT) shares moved
Piero Cingari

Wed Jul 22, 2026

Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88

Stocks split as oil climbs on the 11th night of Iran strikes and Super Micro rockets 26% on a record backlog, while the Nasdaq slips ahead of Alphabet, Tesla.
Avi Kapoor

Wed Jul 22, 2026

Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday. The Dow traded up 0.40% to 52,432.64 while the NASDAQ declined 0.01% to 25,834.80. The
Avi Kapoor

Wed Jul 22, 2026

CME Group, Weatherford International, RPM International And Other Big Stocks Moving Higher On Wednesday

Dow Jones up 200 pts, CME Group shares rise on upbeat earnings. Super Micro Computer, Arrowhead Pharma, Phoenix Asia, Everforth also gain.
Benzinga Insights

Wed Jul 22, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday's pre-market session. The company's market cap stands at $8.2 million. China SXT Pharmaceuticals (NASDAQ:SXTC)

Goldman Sachs

Thu Sep 24, 13:50

hold

confirm
Citigroup

Tue Sep 8, 18:03

buy

initial